Search Result

Results for "

MDA-MB-231 breast tumor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	TNF Receptor (1) Adenosine Receptor (1) Akt (1) AMPK (2) Apoptosis (31) Aurora Kinase (1) AUTACs (1) Autophagy (3) Bcl-2 Family (4) Carbonic Anhydrase (1) Casein Kinase (2) Caspase (4) CDK (6) Cyclin G-associated Kinase (GAK) (1) Discoidin Domain Receptor (1) DNA/RNA Synthesis (2) Dopamine Receptor (1) Drug Derivative (4) Drug Intermediate (1) EGFR (1) Endogenous Metabolite (2) Ephrin Receptor (1) Epigenetic Reader Domain (1) ERK (3) FAK (2) Ferroptosis (2) Galectin (1) Glutathione Peroxidase (1) HDAC (3) Hedgehog (1) Histone Methyltransferase (2) HuR (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Integrin (2) JNK (1) MDM-2/p53 (1) MicroRNA (2) Microtubule/Tubulin (2) MMP (1) Mps1 (1) mTOR (2) NF-κB (3) NO Synthase (2) Oxidative Phosphorylation (1) P-glycoprotein (1) p38 MAPK (3) Parasite (1) PARP (4) PERK (1) Phosphatase (2) Photosensitizer (1) PI3K (3) PROTACs (3) Quinone Reductase (1) Radionuclide-Drug Conjugates (RDCs) (1) Ras (1) Reactive Oxygen Species (ROS) (4) ROCK (1) ROR (1) Serotonin Transporter (1) Sialyltransferase (2) STAT (2) TAM Receptor (1) TGF-β Receptor (1) Topoisomerase (2) VEGFR (1) Wnt (2) β-catenin (1)
By Research Areas:	Cancer (62) Infection (3) Inflammation/Immunology (3) Neurological Disease (1)

By Targets:

TNF Receptor (1)

Adenosine Receptor (1)

Akt (1)

AMPK (2)

Apoptosis (31)

Aurora Kinase (1)

AUTACs (1)

Autophagy (3)

Bcl-2 Family (4)

Carbonic Anhydrase (1)

Casein Kinase (2)

Caspase (4)

CDK (6)

Cyclin G-associated Kinase (GAK) (1)

Discoidin Domain Receptor (1)

DNA/RNA Synthesis (2)

Dopamine Receptor (1)

Drug Derivative (4)

Drug Intermediate (1)

EGFR (1)

Endogenous Metabolite (2)

Ephrin Receptor (1)

Epigenetic Reader Domain (1)

ERK (3)

FAK (2)

Ferroptosis (2)

Galectin (1)

Glutathione Peroxidase (1)

HDAC (3)

Hedgehog (1)

Histone Methyltransferase (2)

HuR (1)

Indoleamine 2,3-Dioxygenase (IDO) (1)

Integrin (2)

JNK (1)

MDM-2/p53 (1)

MicroRNA (2)

Microtubule/Tubulin (2)

MMP (1)

Mps1 (1)

mTOR (2)

NF-κB (3)

NO Synthase (2)

Oxidative Phosphorylation (1)

P-glycoprotein (1)

p38 MAPK (3)

Parasite (1)

PARP (4)

PERK (1)

Phosphatase (2)

Photosensitizer (1)

PI3K (3)

PROTACs (3)

Quinone Reductase (1)

Radionuclide-Drug Conjugates (RDCs) (1)

Ras (1)

Reactive Oxygen Species (ROS) (4)

ROCK (1)

ROR (1)

Serotonin Transporter (1)

Sialyltransferase (2)

STAT (2)

TAM Receptor (1)

TGF-β Receptor (1)

Topoisomerase (2)

VEGFR (1)

Wnt (2)

β-catenin (1)

By Research Areas:

Cancer (62)

Infection (3)

Inflammation/Immunology (3)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: BRK Large Tumor Suppressor (LATS) TNF Receptor BCRP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-119272

EF24 2 Publications Verification	ERK Caspase NF-κB Apoptosis p38 MAPK Reactive Oxygen Species (ROS)	Inflammation/Immunology Cancer
EF24, a curcumin analogue, is an NF-kB inhibitor with great anti-tumor efficacy and oral bioavailability via deactivation of the MAPK/ERK signaling pathway in oral squamous cell carcinoma (OSCC). EF24 is active against melanoma and breast cancer cell lines with GI₅₀ values of 0.7 μM and 0.8 μM, respectively. EF24 induces cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells and DU-145 human prostate cancer cells. EF24 increases the levels of activated caspase 3 and 9, and decreases the phosphorylated forms of MEK1 and ERK .

HY-N0841

Bruceine A 3 Publications Verification Dihydrobrusatol; NSC310616	Parasite NF-κB p38 MAPK Phosphatase Apoptosis	Infection Cancer
Bruceine A (Dihydrobrusatol) is a natural quassinoid. Bruceine A is an inhibitor of parasites, NF-κB, and PFKFB4 (K_d: 44 nM). Bruceine A is an activator of P38α MAPK. Bruceine A has antiparasitic activity. Bruceine A has antitumor activity and inhibits cancer cell migration. Bruceine A blocks the cell cycle and induces apoptosis. Bruceine A can be used in parasites, pancreatic cancer, and breast cancer research .

HY-173496

ST6GAL1-IN-1	Sialyltransferase Integrin VEGFR Akt	Cancer
ST6GAL1-IN-1 is an orally active selective ST6GAL1 inhibitor (IC₅₀ = 20 μM). ST6GAL1-IN-1 exhibits high antimetastatic potential, effectively inhibiting the migration of MDA-MB-231 cells at noncytotoxic concentrations. ST6GAL1-IN-1 can disrupt integrin sialylation in MDA-MB-231 cells. ST6GAL1-IN-1 inhibits tumor angiogenesis and cancer metastasis via the Integrin/VEGFR2-mediated signaling pathway. ST6GAL1-IN-1 effectively suppresses both tumor growth and cancer metastasis on the MDA-MB-231 xenograft model. ST6GAL1-IN-1 can be used for the study of Triple-negative breast cancer (TNBC) .

HY-18285

Longdaysin	Wnt Casein Kinase ERK CDK	Cancer
Longdaysin is a inhibitor of the Wnt/β-catenin signaling pathway, which exerts antitumor effect through blocking CK1δ/ε-dependent Wnt signaling. Longdaysin inhibits CK1α, CK1δ, CDK7, and ERK2 with IC₅₀s of 5.6 µM, 8.8 µM, 29 µM, and 52 µM, respectively .

HY-P991577

DS-8895 DS-8895A	Ephrin Receptor	Cancer
DS-8895(DS-8895A) is an anti-EphA2 monoclonal antibody with specific binding to EphA2 receptors and EphA2-expressing cells. DS-8895, when conjugated with ⁸⁹Zr, ¹¹¹In, or ¹²⁵I, supports molecular imaging of EphA2 expression in xenograft models. DS-8895 allows noninvasive measurement of EphA2 expresssion in tumors in vivo. .

HY-W111581

Copper(II) diethyldithiocarbamate 1 Publications Verification Diethyldithiocarbamic acid copper salt	Apoptosis Caspase	Cancer
Copper(II) diethyldithiocarbamate (Diethyldithiocarbamic acid copper salt) is a Copper(II) and diethyldithiocarbamate coordination polymer. Copper(II) diethyldithiocarbamate binds tightly to NPL4 and induces its aggregation, disrupting the p97-NPL4-UFD1 pathway. Copper(II) diethyldithiocarbamate causes ubiquitinated proteins accumulation and impairs waste proteins degradation, thus resulting in cell apoptosis. Copper(II) diethyldithiocarbamate inhibits tumor growth in MDA-MB-231 xenograft mice models. Copper(II) diethyldithiocarbamate can be used for the research of cancer, such as breast cancer .

HY-158045

PROTAC PARP1 degrader-1	PROTACs PARP	Cancer
PROTAC PARP1 degrader-1 is a PARP1 PROTAC degrader with a DC₅₀ value of 252.5 nM. PROTAC PARP1 degrader-1, combined with Daunorubicin (HY-13062A), induces the accumulation of cytoplasmic DNA fragments, activates the cGAS/STING innate immune pathway, and remodels the tumor microenvironment. PROTAC PARP1 degrader-1 can be used in research related to breast cancer .

HY-156096

HDAC3-IN-2	HDAC Histone Methyltransferase Caspase Apoptosis DNA/RNA Synthesis	Cancer
HDAC3-IN-2 (compound 4i) is a pyrazinyl hydrazide-based HDAC3 inhibitor (IC₅₀: 14 nM) that efficiently targets triple-negative breast cancer cells. HDAC3-IN-2 is cytotoxic with an IC₅₀ of 0.55 μM against 4T1 and an IC₅₀ of 0.74 μM against MDA-MB-231. HDAC3-IN-2 has anti-tumor efficacy in vivo in tumor-bearing mouse models, selectively increasing the acetylation levels of H3K9, H3K27 and H4K12, increasing the contents of apoptosis-related caspase-3, caspase-7 and cytochrome c, and reducing Proliferation-related Bcl-2, CD44, EGFR, and Ki-67 levels .

HY-120275

CYD-2-11	Bcl-2 Family Apoptosis	Cancer
CYD-2-11 is a selective Bax agonist with a K_i value of 34.1 nM. CYD-2-11 induces cell apoptosis and shows antiproliferative activity to breast cancer MDA-MB-231 and MCF-7 cell lines with IC₅₀ values of 3.22 and 3.81 μM, respectively. CYD-2-11 suppresses tumor growth in MDA-MB-231 tumor models. CYD-2-11 can be used for the research of breast and lung cancer .

HY-N6990

Anhydrosecoisolariciresinol	Others	Cancer
Anhydrosecoisolariciresinol is from the flower of Wedelia biflora, has anti-tumor activities . Anhydrosecoisolariciresinol decreases the growth of human breast cancer MCF-7 and MDA-MB-231 cell lines .

HY-172888

SPP-037	Endogenous Metabolite Sialyltransferase FAK Integrin	Cancer
SPP-037 is an orally active and selective inhibitor of ST6GAL1 (IC₅₀ = 3.59 μM). SPP-037 inhibits integrin α2,6-sialylation and integrin-FAK-paxillin pathway. SPP-037 inhibits cancer cell proliferation, migration and exhibits antiangiogenic activity. SPP-037 has anti-tumor activity in MDA-MB-231 xenograft mouse model. SPP-037 can be used for the research of triple-negative breast cancer .

HY-145260

BRD4/CK2-IN-1	Epigenetic Reader Domain Casein Kinase Apoptosis Autophagy	Cancer
BRD4/CK2-IN-1 is the first highly effective and oral active dual-target inhibitor of BRD4/CK2 (bromodomain-containing protein 4/casein kinase 2), with IC₅₀s of 180 nM and 230 nM for BRD4 and CK2, respectively. BRD4/CK2-IN-1 has strong anticancer activity without obvious toxicities. BRD4/CK2-IN-1 induces apoptosis and autophagy-associated cell death in triple-negative breast cancer (TNBC)

HY-178367

PFKFB4-IN-1	Phosphatase Apoptosis Caspase PARP	Cancer
PFKFB4-IN-1 is a potent and selective ATP-competitive PFKFB4 inhibitor (IC₅₀ = 4.50 μM) that reduces intracellular PFKFB4 protein levels. PFKFB4-IN-1 exhibits >12-fold selectivity over PFKFB1/4 and PFKFB3/4. PFKFB4-IN-1 inhibits cancer cell proliferation, induces apoptosis, and inhibits cell migration. PFKFB4-IN-1 inhibits tumor growth in the MDA-MB-231 xenograft mouse model. PFKFB4-IN-1 can be used for breast, lung and liver cancer research .

HY-168996

LA-CB1	CDK Apoptosis	Cancer
LA-CB1 is an Abemaciclib (HY-16297A) derivative that targets CDK4/6 and promotes its degradation via the ubiquitin-proteasome pathway, thereby disrupting the CDK4/6-Cyclin D1-Rb-E2F axis and inducing G0/G1 cell cycle arrest and apoptosis. LA-CB1 exhibits antiproliferative activity against MDA-MB-231 cells, with an IC₅₀ of 0.27 µM, and effectively inhibits epithelial-mesenchymal transition (EMT), cell migration, invasion, and angiogenesis. In highly aggressive models such as triple-negative breast cancer (TNBC), LA-CB1 significantly suppresses tumor growth in a dose-dependent manner. LA-CB1 holds potential for research in the field of breast cancer .

HY-115507

NMac1	AMPK mTOR ERK Oxidative Phosphorylation Reactive Oxygen Species (ROS) Ras	Cancer
NMac1 is an orally active Nm23/NDPK activator. NMac1 directly binds to Nm23-H1 and activates the NDPK activity of recombinant Nm23-H1 with an EC₅₀ of 10.7 uM. NMac1 induces AMPK activation and inhibits mTOR and ERK, leading to mitochondrial OXPHOS dysregulation and suppressing mitochondrial ROS production, which in turn induces mitochondrial dysfunction in MDA-MB-231 cells. NMac1 inhibits Complex I activity and suppresses changes in morphology and actin cytoskeleton organization following Rac1 activation in MDA-MB-231 cells. NMac1 inhibits tumor invasion, migration and metastasis. NMac1 is useful for studying metastatic tumors, such as breast cancer. NMac1 can be isolated from the ginger cassumunar Roxb .

HY-175846

TQFL13	Drug Derivative Apoptosis	Cancer
TQFL13 is derivative of Thymoquinone (TQ) (HY-D0803) with potent anti-breast cancer activity. TQFL13 exhibits higher cytotoxicity against breast cancer cells (BT549, MDA-MB-231, 4T1). TQFL13 increases apoptosis and blocks the cell cycle at S and G2/G1 phases in breast cancer cells. TQFL13 shows dose-dependent anti-tumor efficacy in mouse breast cancer allograft model. TQFL13 can be used for the study of breast cancer .

HY-103043

Pz 285	Others	Cancer
Pz 285 is an anti-cancer agent. Pz 285 shows significant inhibitory effect on the viability of MDA-MB-231 breast cancer cells, with an IC₅₀ of 15.0 μM. Pz 285 exhibits remarkable antitumor effects in the mouse tumor xenograft model constructed with highly lung-metastatic MDA-MB-231 LM24 Her2+ breast cancer cells. Pz 285 can be used for the study of breast cancer, especially metastatic breast cancer .

HY-175497

ROR1-IN-4	ROR Apoptosis Bcl-2 Family PARP	Cancer
ROR1-IN-4 is a selective ROR1 inhibitor with a K_d of 52 nM. ROR1-IN-4 shows potent anti-proliferative activity against TNBC cell line MDA-MB-231 (IC₅₀ = 75 nM). ROR1-IN-4 reduces colony formation, induces apoptosis and inhibits the phosphorylation of ROR1 (Tyr786) in MDA-MB-231 cells. ROR1-IN-4 demonstrates superior anti-tumor efficacy in nude mice bearing MDA-MB-231 subcutaneous xenografts. ROR1-IN-4 can be used for the study of triple-negative breast cancer (TNBC) .

HY-20176

2,4-Dichlorothieno[3,2-d]pyrimidine	Drug Intermediate Adenosine Receptor PI3K	Infection
2,4-Dichlorothieno[3,2-d]pyrimidine is a thienopyrimidine scaffold and a key synthetic precursor, which is widely used for constructing 4-arylthieno[3,2-d]pyrimidine compounds. 2,4-Dichlorothieno[3,2-d]pyrimidine serves for the development of 4-arylthieno[3,2-d]pyrimidine-based human adenosine A2a receptor antagonists, as well as thienopyrimidine-based PI3K-α inhibitors. In addition, 2,4-Dichlorothieno[3,2-d]pyrimidine has potential application value in studies related to whipworm disease .

HY-179468

STAT3-IN-49	STAT	Cancer
STAT3-IN-49 (compound B16) is a potent and selective STAT3 inhibitor. STAT3-IN-49 binds to the SH2 domain of STAT3, thereby suppressing its phosphorylation and nuclear translocation. STAT3-IN-49 inhibits triple-negative breast cancer (TNBC) cell migration, invasion, and colony formation. STAT3-IN-49 inhibits tumor growth in an MDA-MB-231 xenograft mouse model. STAT3-IN-49 can be used for TNBC research .

HY-178343

Aurora A-IN-5	Aurora Kinase Apoptosis	Cancer
Aurora A-IN-5 is a potent and highly selective Aurora A inhibitor (IC₅₀ = 0.02 μM), showing 362-fold selectivity for over Aurora B. Aurora A-IN-5 shows its selectivity through unique C−H/π interactions, enhanced hydrophobic contacts, an open binding pocket, and tighter protein packing. Aurora A-IN-5 suppresses Aurora A autophosphorylation, thereby inhibiting cancer cell proliferation by inducing G2/M phase arrest, triggering apoptosis, and suppressing colony formation. Aurora A-IN-5 inhibits tumor growth in MDA-MB-231 xenograft mouse models. Aurora A-IN-5 can be used for breast, cervical, prostate, and lymphoma cancer research .

HY-176220

GPX4-AUTAC	AUTACs Autophagy Glutathione Peroxidase Ferroptosis	Cancer
GPX4-AUTAC is a GPX4-targeting autophagy-mediated degrader (AUTAC). GPX4-AUTAC consists of an inhibitor ML162-yne (HY-153748), a degradation tag FBnG (HY-W073762) and a glycol linker (HY-W021401). GPX4-AUTAC promotes the ubiquitination of GPX4 by E3 ligase TRAF6, and enhances the binding with GPX4 and p62, leading to the selective autophagy-dependent degradation of GPX4. GPX4-AUTAC significantly induces ferroptosis and shows a potent anti-cancer activity in breast cancer cells, breast cancer-derived organoids (PDOs) and MDA-MB-231 tumor xenograft mice model, with potent synergistic effects when combined with Sulfasalazine (SAS) (HY-14655) or chemotherapy drugs (Paclitaxel (HY-B0015) or Cisplatin (HY-17394)) .

HY-144638

JMX0293	Apoptosis	Cancer
JMX0293 is an O-alkylamino-tethered salicylamide derivative compound. JMX0293 maintains good potency against MDA-MB-231 cell line (IC₅₀ = 3.38 μM) while exhibiting very low toxicity against human non-tumorigenic breast epithelial cell line MCF-10A (IC₅₀> 60 μM). JMX0293 inhibits STAT3 phosphorylation and contribute to apoptosis in TNBC MDA-MB-231 cells. JMX0293 significantly suppresses MDA-MB-231 xenograft tumor growth in vivo without significant toxicity .

HY-106159

SB-T-101141	Reactive Oxygen Species (ROS) p38 MAPK JNK PERK Ferroptosis	Cancer
SB-T-101141 is a novel taxane. SB-T-101141 effectively induces a noncanonical ferroptosis to overcome Paclitaxel (HY-B0015) resistance of breast cancer. SB-T-101141 facilitates the production of iron and ferrous ions and ROS. SB-T-101141 stably binds to KHSRP to inhibit the iron-dependent expression of CISD1 related to iron homeostasis. SB-T-101141 synergistically enhances the iron-dependent activation of JNK and PERK pathways via KHSRP. SB-T-101141 suppresses breast tumor growth in MCF-7(PR)/MDA-MB-231(PR) or KHSRP knock-down MCF-7 xenograft mice model .

HY-175544

anti-TNBC agent-10	Drug Derivative	Cancer
anti-TNBC agent-10 is an anti-TNBC agent. anti-TNBC agent-10 shows potent anti-TNBC activity against BT549 cells (IC₅₀ = 0.018 μM) and maintains activity against MDA-MB-231 cells (IC₅₀ = 4.16 μM). anti-TNBC agent-10 9 demonstrates significant anti-tumor efficacy in mice bearing subcutaneous MDA-MB-231 TNBC xenografts. anti-TNBC agent-10 can be used for the study of triple-negative breast cancer (TNBC) .

HY-152536

iNOS inhibitor-10	NO Synthase	Cancer
iNOS inhibitor-10 is an iNOS inhibitor (IC₅₀: 65 nM). iNOS inhibitor-10 has antiproliferative effect against triple negative breast cancer cells .

HY-163760

ZM-32	HuR MMP	Cancer
ZM-32 is an inhibitor for human antigen R (HuR), that downregulates the expression of VEGF-A and MMP9, and thus inhibits breast cancer tumor angiogenesis. ZM-32 exhibits broad-spectrum anti-proliferative effects in a variety of cancer cell lines, and exhibits antitumor efficacy against MDA-MB-231 in mouse models .

HY-155180

FD2056	PI3K	Cancer
FD2056 is a potent and orally active PI3K inhibitor. FD2056 inhibits PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ with IC₅₀s of 0.30, 0.80, 1.10, 0.42 nM. FD2056 also inhibits CDK2-CyclinA2 and CDK4-CyclinD3 with IC₅₀ of 115.95 and 2782.15 nM. FD2056 inhibits breast cancer cell proliferation with IC₅₀s of 1.06, 0.04, 1.40 μM for MDA-MB-231, MDA-MB-468, MCF-7 cells. FD2056 also induces cancer apoptosis and inhibits tumor growth .

HY-P10511

Pantinin-3	Apoptosis	Infection Cancer
Pantinin-3 is an antimicrobial peptide with antitumor activity found in the venom of the emperor scorpion (Pandinus imperator). Pantinin-3 shows selective toxicity against breast cancer cells (MDA-MB-231) and prostate cancer cells (DU-145). Pantinin-3 can induce apoptosis in tumor cells. Pantinin-3 can be used in cancer research .

HY-N15636

Coccinine (-)-Coccinine	Serotonin Transporter P-glycoprotein	Neurological Disease Cancer
Coccinine ((-)-Coccinine) is a weak inhibitor of SERT (IC₅₀: 196.3 μM; K_i: 106.8 μM) and P-gp (IC₅₀: 0.96 mM). Coccinine exhibits significant anti-tumor activity against various cancer cell lines, such as breast cancer (MCF7, Hs578T, MDA-MB-231), colon cancer (HCT-15), and lung cancer (A549). Coccinine can be used in the research of tumors and neurological diseases .

HY-135276

Targaprimir-96	MicroRNA Apoptosis	Cancer
Targaprimir-96 is a potent inhibitor of microRNA-96 (miR-96) processing. Targaprimir-96 selectively modulates miR-96 production in cancer cells and triggers apoptosis. Targaprimir-96 binds primary miR-96 (pri-miR-96) with low nanomolar affinity. Targaprimir-96 directly engages pri-miR-96 in breast cancer cells and is ineffective on healthy breast cells .

HY-175834

DNA/TOP2A-IN-1	Topoisomerase Reactive Oxygen Species (ROS) Apoptosis Microtubule/Tubulin	Cancer
DNA/TOP2A-IN-1 is an inhibitor of DNA and TOP2A. DNA/TOP2A-IN-1 selectively binds to TOP2A, not TOP2B, and interacts with DNA and TOP2A to form a stable DM1-TOP2A-DNA ternary complex. DNA/TOP2A-IN-1 induces DNA damage, increases reactive oxygen species (ROS) and triggers apoptosis in triple-negative breast cancer (TNBC) cells. DNA/TOP2A-IN-1 disrupts microtubule distribution and induces cell cycle arrest. DNA/TOP2A-IN-1 shows strong antiproliferative activity and inhibits cell migration. DNA/TOP2A-IN-1 inhibits tumor growth and can be used for TNBC research .

HY-174992

Apoptosis inducer 39	Apoptosis Bcl-2 Family	Cancer
Apoptosis inducer 39 is an apoptosis inducer with IC₅₀s of 4.53 and 15.42 μM against MDA-MB-231 and A549 cells. Apoptosis inducer 39 exerts in vitro anti-tumor activity by decreasing the expression of the anti-apoptotic protein Bcl-2 while increasing the expression of the pro-apoptotic protein Bax. Apoptosis inducer 39 can be used for the study of breast cancer and non-small lung cancer .

HY-176713

KWZY-11	PARP CDK Wnt β-catenin Apoptosis	Cancer
KWZY-11 (Compound 11) is a potent PARP/CDK6 dual inhibitor with IC₅₀ values of 156.8, 197.3, and 13.3 nM for PARP1, PARP2, and CDK6, respectively. KWZY-11 inhibits tumor cell proliferation by regulating the Wnt/β-catenin signaling pathway. KWZY-11 induces excessive DNA damage and apoptosis in MDA-MB-231 breast cancer cells .

HY-156077

anti-TNBC agent-2	Apoptosis DNA/RNA Synthesis	Cancer
anti-TNBC agent-2 (3j) an anti-Triple negative breast cancer (TNBC) purine derivative. anti-TNBC agent-2 induces MDA-MB-231 cells apoptosis, and inhibits its migration and angiogenesis. anti-TNBC agent-2 inhibits tumor growth and metastasis and reduces the expression of Ki67 and CD31 protein in TNBC xenograft models. anti-TNBC agent-2 can be used for Triple negative breast cancer (TNBC) research .

HY-119948

AKCI	Cyclin G-associated Kinase (GAK) MDM-2/p53	Cancer
AKCI is a type of AURKC-IκBα interaction inhibitor, with an IC₅₀ value of 24.9 μM. In MDA-MB-231 cells, AKCI can induce G2/M cell cycle arrest by regulating the p53/p21/CDC2/cyclin B1 pathway, inhibit cell migration and invasion, and reduce colony formation and tumor growth. AKCI can be used for research on breast cancer .

HY-146452

Anticancer agent 57	Apoptosis	Cancer
Anticancer agent 57 (compound 14) potently inhibits MDA-MB-231, MDA-MB-468, and MCF-7 cell lines, with IC₅₀s of 6.43 ~ 8.00 μM. Anticancer agent 57 induces cell cycle arrest and significantly promotes apoptosis. Anticancer agent 57 inhibits tumor growth in nude mice xenografted with MADMB-231 cells. Anticancer agent 57 can be used for researching triple negative breast cancer (TNBC) .

HY-170947

Antitumor agent-195	STAT Quinone Reductase	Cancer
Antitumor agent-195 (compound 16c) is a dual targeting agent of STAT3 and NQO1. Antitumor agent-195 significantly inhibits phosphorylation of STAT3 at Tyr705 at a concentration of 1 μM and effectively induce Apoptosis in MDAMB-231 and MDA-MB-468 breast cancer cells. Antitumor agent-195 as a NQO1 substrate strongly increases ROS generation and causes severe DNA damage in a dose-dependent manner. Antitumor agent-195 shows encouraging anti-tumor efficacy in the MDA-MB-231 xenograft model .

HY-P10393

ERα17p ERα (295-311)	Apoptosis	Cancer
ERα17p (ERα 295-311) is the epitope of the CaM binding site on the estrogen receptor α (ER), which interacts with calmodulin (CaM) in a calcium-dependent manner. ERα17p regulates the migration of cancer cells MCF-7, SK-BR-3, T47D, and MDA-MB-231 through Rho/ROCK and PI3K/Akt signaling pathways. ERα17p inhibits proliferations of breast cancer cells, induces apoptosis, and inhibits tumor growth in mouse models .

HY-175638

Carbonic anhydrase-IN-35	Carbonic Anhydrase Apoptosis Bcl-2 Family CDK	Cancer
Carbonic anhydrase-IN-35 is a selective carbonic anhydrase (CA) inhibitor. Carbonic anhydrase-IN-35 potently inhibits tumor-associated hCA IX (K_i = 0.6 nM) and hCA XII (K_i = 2.2 nM). Carbonic anhydrase-IN-35 induces apoptosis in MCF-7 cells by elevating Bax, reducing Bcl-2, and downregulating CDK4/6. Carbonic anhydrase-IN-35 exhibits potent cytotoxicity against MCF-7 (IC₅₀ = 0.3975 μM normoxic/0.6575 μM hypoxic), MCF-7-ADR (IC₅₀> = 0.3975 μM normoxic/4.488 μM hypoxic), MDA-MB-231, and 4T1 breast cancer cells. Carbonic anhydrase-IN-35 can be used for the study of breast cancer .

HY-168650

ROCK/HDAC-IN-1	ROCK HDAC	Inflammation/Immunology Cancer
ROCK/HDAC-IN-1 (Compound 10h) is an orally active ROCK/HDAC inhibitor. ROCK/HDAC-IN-1 inhibits ROCK1/2 (IC₅₀: 254.9 nM, 58.18 nM) and HDAC1/2/3/6/8 (IC₅₀: 9.09, 8.03, 6.26, 0.41, 7.69 nM). ROCK/HDAC-IN-1 stimulates the activation of DAMPs, specifically Calreticulin (CRT) exposure and HMGB1 release, indicating that it is a potential ICD inducer.. ROCK/HDAC-IN-1 has antiproliferative activity against breast cancer cells (IC₅₀: 0.37 μM for MDA-MB-231 cell), and inhibits tumor growth and activates T cells without apparent toxicity .

HY-W010713

Meso-tetraphenylchlorin Fimaporfin free base	Photosensitizer	Cancer
Meso-tetraphenylchlorin (TPCS2a) is a photosensitizer with poor water solubility, which limits its use in the blood circulation. However, TPCS2a@NPs nanoparticles can be prepared based on polylactic-co-polyethylene glycol acid (PLGA) polymer core loaded with TPCS2. Such nanoparticles can be coated with mesenchymal stem cell-derived plasma membranes (mMSCs) to form mMSC-TPCS2a@NPs, which prolongs blood circulation time and improves tumor targeting ability. Compared with uncoated TPCS2a@NPs, mMSC-TPCS2a@NPs can reduce macrophage uptake by 54% to 70% under different conditions. Both nanoparticle forms are effectively accumulated in MCF7 and MDA-MB-231 breast cancer cells, while uptake in normal breast epithelial cells MCF10A is significantly lower .

HY-162805

iNOS/TopoI-IN-1	NO Synthase Topoisomerase Apoptosis NF-κB	Inflammation/Immunology Cancer
iNOS/TopoI-IN-1 (compound AuL9) is a multi-target hybrid molecule with anti-tumor, anti-inflammatory and antioxidant activities. iNOS/TopoI-IN-1 inhibits the growth of breast cancer cells MCF-7 and MDA MB-231 in vitro with IC₅₀ of 3.5 μM and 6.3 μM, respectively, and induces DNA damage and apoptosis of breast cancer cells by inhibiting human topoisomerase I (TopoI) (K_i=2.72 μM). In addition, NOS/TopoI-IN-1 inhibits the expression of iNOS by inhibiting the activation of NF-kB (K_i=1.49 μM) .

HY-172891

CDK9/HDAC1/HDAC3-IN-1	CDK HDAC Apoptosis	Cancer
CDK9/HDAC1/HDAC3-IN-1 is dual-functional inhibitor of CDK9 and HDAC. CDK9/HDAC1/HDAC3-IN-1 inhibits the protein activity of CDK9/HDAC/HDAC3 with IC₅₀s of 0.17  μM, 1.73  μM and 1.11 μM for CDK9, HDAC1, and HDAC3, respectively. CDK9/HDAC1/HDAC3-IN-1 inhibits cancer cells by inducing cell apoptosis and cell cycle arrest in the G2/M phase, as well as tumor growth in a murine TNBC MDA-MB-231 xenograft model. CDK9/HDAC1/HDAC3-IN-1 has a broad-spectrum anti-cancer activity, such as breast cancer, cervical cancer, and liver cancer .

HY-P10853

Bacilotetrin C analogue	Autophagy	Cancer
Bacilotetrin C analogue is cytotoxic to triple-negative breast cancer cell line MDA-MB-231 with an IC₅₀ of 0.48 μM. Bacilotetrin C analogue can induce tumor cell autophagy and has anti-tumor activity .

HY-163113

Anticancer agent 180	Endogenous Metabolite	Cancer
Anticancer agent 180 (compound 4) is a secondary metabolite present in fungal strains and extracted through physical interaction with Streptomyces sp. Anticancer agent 180 has potential anti-tumor activity and can inhibit the migration of MDA-MB-231 breast cancer cells .

HY-179679

FAK-IN-29	FAK Apoptosis	Cancer
FAK-IN-29 is a selective FAK inhibitor with an IC₅₀ of 0.5 nM. FAK-IN-29 can inhibit the proliferation and colony formation of MDA-MB-231 cells, and induce cell cycle arrest and apoptosis. FAK-IN-29 exhibits antitumor activity and can be used for the research of tumors such as triple-negative breast cancer .

HY-179430

TTK-IN-5	Mps1	Cancer
TTK-IN-5 is an orally active covalent threonine tyrosine kinase (TTK) inhibitor with selectivity (IC₅₀ = 8.918 nM). TTK-IN-5 exhibits anti-proliferative potencies against MDA-MB-231, A2780, HCT116, HCC1569 and MKN1 cell lines (IC₅₀ values of 0.113 μM, 0.476 μM, 3.136 μM, 3.649 μM, and 1.856 μM, respectively). TTK-IN-5 potently suppresses tumor growth without notable toxicity in A2780 and MDA-MB-231 xenograft mouse models. TTK-IN-5 can be used for the research of cancer such as breast cancer and ovarian cancer .

HY-135276A

Targaprimir-96 TFA	MicroRNA Apoptosis	Cancer
Targaprimir-96 TFA is a potent inhibitor of microRNA-96 (miR-96) processing. Targaprimir-96 TFA selectively modulates miR-96 production in cancer cells and triggers apoptosis. Targaprimir-96 TFA binds primary miR-96 (pri-miR-96) with low nanomolar affinity. Targaprimir-96 TFA directly engages pri-miR-96 in breast cancer cells and is ineffective on healthy breast cells .

HY-122181A

OTS186935 trihydrochloride	Histone Methyltransferase	Cancer
OTS186935 trihydrochloride is a protein methyltransferase SUV39H2 inhibitor with an IC₅₀ of 6.49 nM. OTS186935 trihydrochloride shows significant inhibition of tumor growth in mouse xenograft models without any detectable toxicity. OTS186935 trihydrochloride regulates the production of γ-H2AX in cancer cells .

Cat. No.	Product Name	Target	Research Area

HY-P10511

Pantinin-3	Apoptosis	Infection Cancer
Pantinin-3 is an antimicrobial peptide with antitumor activity found in the venom of the emperor scorpion (Pandinus imperator). Pantinin-3 shows selective toxicity against breast cancer cells (MDA-MB-231) and prostate cancer cells (DU-145). Pantinin-3 can induce apoptosis in tumor cells. Pantinin-3 can be used in cancer research .

HY-P10393

ERα17p ERα (295-311)	Apoptosis	Cancer
ERα17p (ERα 295-311) is the epitope of the CaM binding site on the estrogen receptor α (ER), which interacts with calmodulin (CaM) in a calcium-dependent manner. ERα17p regulates the migration of cancer cells MCF-7, SK-BR-3, T47D, and MDA-MB-231 through Rho/ROCK and PI3K/Akt signaling pathways. ERα17p inhibits proliferations of breast cancer cells, induces apoptosis, and inhibits tumor growth in mouse models .

HY-P10853

Bacilotetrin C analogue	Autophagy	Cancer
Bacilotetrin C analogue is cytotoxic to triple-negative breast cancer cell line MDA-MB-231 with an IC₅₀ of 0.48 μM. Bacilotetrin C analogue can induce tumor cell autophagy and has anti-tumor activity .

HY-P11590

WGYRGFYC	EGFR	Cancer
WGYRGFYC (WC8) is a selective HER2-targeting peptide that binds specifically to HER2 by mimicking the antigen-binding site of trastuzumab. The DOTA precursor of WGYRGFYC has a K_D of 61.20 nM for HER2. WGYRGFYC enables specific and highly sensitive detection of HER2 expression in HER2-positive breast cancer cells and tumor tissues, and monitors the dynamic downregulation of HER2 expression. WGYRGFYC rapidly distributes to target tissues and is efficiently cleared from non-target tissues via the kidneys, generating an ideal tumor-to-background ratio in imaging; it is a component of the PET radiotracer Ga-DOTA-WC8. WGYRGFYC exhibits no significant cytotoxicity in breast cancer cells, and can be used for non-invasive imaging diagnosis and therapeutic efficacy evaluation of HER2-positive breast cancer .

Cat. No.	Product Name	Target	Research Area	Image

HY-P991577

DS-8895 DS-8895A	Ephrin Receptor	Cancer
DS-8895(DS-8895A) is an anti-EphA2 monoclonal antibody with specific binding to EphA2 receptors and EphA2-expressing cells. DS-8895, when conjugated with ⁸⁹Zr, ¹¹¹In, or ¹²⁵I, supports molecular imaging of EphA2 expression in xenograft models. DS-8895 allows noninvasive measurement of EphA2 expresssion in tumors in vivo. .

HY-P992340

CTB006	Radionuclide-Drug Conjugates (RDCs) TNF Receptor	Cancer
CTB006 is a monoclonal antibody targeting a humanized chimeric recombinant anti-DR5. CTB006 specifically binds to and activates DR5, thereby inducing tumor cell apoptosis, inhibiting tumor growth and reducing tumor drug resistance. ¹⁷⁷Lu-radiolabeled CTB006 can deliver targeted radiotherapy to tumor cells; while ⁸⁹Zr- or ¹⁷⁷Lu-labeled CTB006 can serve as a PET/CT imaging agent for detecting DR5 expression levels in preclinical tumor models and screening cancers with DR5 overexpression. CTB006 can be applied to research related to gastrointestinal cancer, colorectal cancer and other solid tumors .

HY-P992291

Anti-PL2L60 Antibody (KAO3)	Apoptosis	Cancer
Anti-PL2L60 Antibody (KAO3) is a PL2L60-targeting antibody. Anti-PL2L60 Antibody (KAO3) binds to PL2L60 expressed on tumor cell surfaces, blocking its tumor-promoting functions. Anti-PL2L60 Antibody (KAO3) arrests tumor cell cycle and induces cancer cell apoptosis. Anti-PL2L60 Antibody (KAO3) activates complement to mediate tumor cell lysis. Anti-PL2L60 Antibody (KAO3) can be used for the research of lymphoma, breast cancer, lung cancer, cervical cancer, colon cancer, and melanoma^[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks